|
|
STATEMENT OF NEED
For approximately 80% of children with attention-deficit/hyperactivity disorder
(ADHD), symptoms persist into adolescence and adulthood. These patients experience
a spectrum of disorder-related functional impairments that are associated with significant
educational and occupational underachievement in relation to their intellectual
potential. In terms of individual and societal cost, the estimated loss of workforce
productivity per year is $8,900 to $15,400 per person with ADHD.
The prevalence of ADHD among adults has been estimated at 4.4% in the United States.
Unfortunately, a majority of adults with ADHD ages 18 to 44 are undiagnosed or untreated.
In the National Comorbidity Survey Replication, only 11% reported treatment for
ADHD within the previous 12 months; however, many ADHD patients in the sample were
in treatment for a comorbid psychiatric disorder. Of the patients receiving care
for a comorbid psychiatric disorder, 75% were not being treated for their ADHD.
Patients may have not only diagnosis-confounding comorbid psychiatric conditions,
but also medical conditions that should be considered before initiating pharmacologic
treatment for ADHD.
Considering the significant impact of ADHD-associated symptoms, risks, and impairments
in adolescents and adults, as well as the complexity involved in appropriate diagnosis
and treatment, this initiative will concentrate on core clinical information pertinent
to recognizing, diagnosing, and managing ADHD in late adolescence and adulthood.
Learning Objectives
1. You will be better able to recognize older adolescents and adults who should
be screened for ADHD, and to diagnose ADHD in these age
groups.
2. You will be able to develop a multimodal treatment plan tailored to the individual
patient, which may include medication, education, psychosocial
treatment, organizational training, and accommodations in school and at work.
3. You will be able to select and titrate pharmacologic treatments that affect symptomatic
behavior and improve the functioning of your patients with
ADHD, and to employ strategies for encouraging patient adherence to treatment.
Intended Audience
Psychiatrists, primary care physicians, and other health care providers who care
for patients with ADHD
Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing medical education
for physicians.
Veritas Institute for Medical Education, Inc. designates this educational activity
for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians
should only claim credit commensurate with the extent of their participation in
the activity.
This activity has been reviewed and is acceptable for up to 1.5 Prescribed credits
by the American Academy of Family Physicians.
Financial and Unlabeled Use Disclosures
The relevant financial relationships of those persons in a position to control the
content of this CME activity will be disclosed prior to the start of the educational
activity. Participants are advised that this CME activity will contain references
to unlabeled/unapproved/investigational uses of drugs to treat ADHD.
Sponsorship and Support
Sponsored by Veritas Institute for Medical Education, Inc.
Supported by an educational grant from McNeil Pediatrics, Division of Ortho-McNeil-Janssen
Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
|